<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030875</url>
  </required_header>
  <id_info>
    <org_study_id>I150</org_study_id>
    <secondary_id>CAN-NCIC-IND150</secondary_id>
    <secondary_id>CDR0000069207</secondary_id>
    <nct_id>NCT00030875</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary&#xD;
      for cancer cell growth.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who&#xD;
      have previously untreated or relapsed mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of bortezomib, in terms of response rate, in patients with&#xD;
           previously untreated or relapsed mantle cell lymphoma.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Correlate suppression of 20S proteasome levels with toxicity of and response to this&#xD;
           drug in these patients.&#xD;
&#xD;
        -  Determine the time to progression and response duration in patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every&#xD;
      3 weeks in the absence of disease progression or unacceptable toxicity. Patients with&#xD;
      complete response (CR) receive 2 courses beyond documentation of CR. Patients with stable&#xD;
      disease receive a maximum of 4 courses. Patients with partial response (PR) continue therapy&#xD;
      until disease progression or for 2 courses beyond documentation of stable PR.&#xD;
&#xD;
      Patients are followed at 4 weeks and then every 3 months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2002</start_date>
  <completion_date type="Actual">December 21, 2009</completion_date>
  <primary_completion_date type="Actual">July 21, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed relapsed or untreated mantle cell lymphoma&#xD;
&#xD;
               -  No refractory disease defined as progression while on chemotherapy or within 1&#xD;
                  month after completion of chemotherapy&#xD;
&#xD;
          -  At least 1 bidimensionally measurable disease site*&#xD;
&#xD;
               -  Lymph nodes at least 1.5 cm by 1.5 cm by spiral CT scan OR&#xD;
&#xD;
               -  Non-nodal lesions (e.g., skin lesion or nodules) at least 1 cm by 1 cm by MRI, CT&#xD;
                  scan, or physical exam NOTE: *Bone lesions are not considered bidimensionally&#xD;
                  measurable disease&#xD;
&#xD;
          -  No pre-existing ascites or pleural effusion&#xD;
&#xD;
          -  No known CNS involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 45% by echocardiogram or MUGA&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No pre-existing shortness of breath greater than grade 1&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled bacterial, fungal, or viral infections&#xD;
&#xD;
          -  No pre-existing edema greater than grade 1&#xD;
&#xD;
          -  No pre-existing neuropathy greater than grade 1&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study compliance&#xD;
&#xD;
          -  No geographical conditions that would preclude study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  Prior rituximab allowed&#xD;
&#xD;
          -  No prior radioactive monoclonal antibody therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior high-dose chemotherapy with stem cell transplantation&#xD;
&#xD;
          -  No more than 2 prior systemic chemotherapy regimens&#xD;
&#xD;
               -  Same chemotherapy combination given for first-line and second-line therapy is&#xD;
                  considered 2 regimens&#xD;
&#xD;
          -  No prior flavopiridol&#xD;
&#xD;
          -  At least 6 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to 25% or more of functioning bone marrow&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose nonmyelosuppressive&#xD;
             radiotherapy) and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy to the sole site of measurable disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior investigational therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew R. Belch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cross Cancer Institute at University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Regional Cancer Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007 Jan;18(1):116-121. doi: 10.1093/annonc/mdl316. Epub 2006 Sep 13.</citation>
    <PMID>16971665</PMID>
  </results_reference>
  <results_reference>
    <citation>Belch A, Kouroukis CT, Crump M: Phase II trial of bortezomib in mantle cell lymphoma. [Abstract] Blood 104(11): A-608, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Assouline S, Belch A, Sehn L, et al.: A phase II study of bortezomib in patients with mantle cell lymphoma. [Abstract] Blood 102 (11 Pt 1): A-3358, 2003.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

